Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador (2023)

Peer-Reviewed Study · Yuliana Jimenez-Gaona, Oscar Vivanco-Galvan, G. Morales-Larreategui, A. Cabrera-Bejarano, Vasudevan Lakshminarayanan · February 22, 2023

Yuliana Jimenez-Gaona et al., 2023-02-22: Mixed-methods survey in rural Loja province, Ecuador, finding that 19% of respondents with cancer used ivermectin-based products alongside conventional treatment, with patients reporting improvement and local specialists stating there is no authorisation for it.

The main findings show that 19% of the participants diagnosed with cancer take medicines based on ivermectin as alternative therapy to the cancer control and treatment without leaving treatment such as chemotherapy, radiotherapy, or immunotherapy

Yuliana Jimenez-Gaona et al., 2023-02-22: Mixed-methods survey in rural Loja province, Ecuador, finding that 19% of respondents with cancer used ivermectin-based products alongside conventional treatment, with patients reporting improvement and local specialists stating there is no authorisation for it. C5. Study type: cross-sectional mixed-methods survey (observation, surveys, interviews) – usage data, not outcomes. Country Ecuador (Universidad Tecnica Particular de Loja; University of Waterloo). N: not stated in the abstract; the paper reports percentages of the surveyed cancer patients. Dose: not standardised – participants used veterinary ivermectin products; the paper notes bovine formulations may contain closantel and other excipients. Comparator: none. Outcome measure: self-reported perception of improvement after the third dose; no clinical endpoints. Funding: not stated in the PubMed record. Disclosures: 'The authors declare no conflict of interest.' The authors themselves conclude that 'there is no scientific knowledge about the application of these treatments in humans' and that the specialists interviewed 'do not recommend their application'. Study type: other.